Cost-effectiveness of the Health X Project for tuberculosis control in China

International Journal of Tuberculosis and Lung Disease

Volumn 18, Issue 8, 2014, Pages 939-945

  Wang, W B ^a   Zhang, H ^b   Petzold, M ^c   Zhao, Q ^a   Xu, Biao ^a   Zhao, G M ^a  

^a FUDAN UNIVERSITY   (China)

^b CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

China; Cost effectiveness; Health X Project; Tuberculosis; World bank loan

Indexed keywords

TUBERCULOSTATIC AGENT;

ARTICLE; BUDGET; CHINA; CHINESE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISABILITY ADJUSTED LIFE YEAR SAVED; FUNDING; GOVERNMENT; HEALTH CARE COST; HEALTH PROGRAM; HEALTH X PROJECT; HUMAN; INCREMENTAL DISABILITY ADJUSTED LIFE YEAR SAVED; MORTALITY; MULTIDRUG RESISTANT TUBERCULOSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; TUBERCULOSIS CONTROL; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; DEVELOPING COUNTRY; DIRECTLY OBSERVED THERAPY; ECONOMICS; ORGANIZATION AND MANAGEMENT; PROGRAM DEVELOPMENT; PROGRAM EVALUATION; PUBLIC HEALTH; QUALITY ADJUSTED LIFE YEAR; TUBERCULOSIS; UNITED NATIONS;

ANTITUBERCULAR AGENTS; CHINA; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DEVELOPING COUNTRIES; DIRECTLY OBSERVED THERAPY; HUMANS; NATIONAL HEALTH PROGRAMS; PROGRAM DEVELOPMENT; PROGRAM EVALUATION; QUALITY-ADJUSTED LIFE YEARS; TUBERCULOSIS; UNITED NATIONS;

EID: 84904578049     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.13.0131     Document Type: Article

References (30)

1. World Health Organization. WHO report, 2010. Global tuberculosis control. WHO/HTM/TB/2010.7. Geneva, Switzerland: WHO, 2010.
2. Ministry of Health, China. Report on nationwide random survey for the epidemiology of tuberculosis in 2000. Beijing, China: MoH, 2002.
3. Kremer K, Glynn J R, Lillebaek T, et al. Definition of the Beijing/W lineage of Mycobacterium tuberculosis on the basis of genetic markers. J Clin Microbiol 2004; 42: 4040-4049. (Pubitemid 39296121)
4. He G X, Zhao Y L, Jiang G L, et al. Prevalence of tuberculosis drug resistance in 10 provinces of China. BMC Infect Dis 2008; 8: 166.
5. Zhao Y, Xu S, Wang L, et al. National survey of drug-resistant tuberculosis in China. N Engl J Med 2012; 366: 2161-2170.
6. Wang L, Liu J, Chin D P. Progress in tuberculosis control and the evolving public-health system in China. Lancet 2007; 369: 691-696.
7. Xianyi C, Fengzeng Z, Hongjin D, et al. The DOTS strategy in China: results and lessons after 10 years. Bull World Health Organ 2002; 80: 430-436.
8. Ma J, Yang G, Shi X. Information technology platform in China's disease surveillance system. Dis Surveill 2006; 21: 1-3.
9. Drummond M F. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford, UK; New York, NY, USA: Oxford University Press, 2005.
10. Wang X, Wu G, Gong Y, et al. Study on the disease economic burden of TB patients with drug resistance in areas of TB control program. Chinese Health Econ 2005; 24: 3.
11. National Center for Disease Control and Prevention C. Report of the 5th National Tuberculosis Epidemiological Sampling Survey. Beijing, China: National Center for Disease Control and Prevention, 2012.
12. Xu B, Dong H J, Zhao Q, et al. DOTS in China - removing barriers or moving barriers? Health Policy Plann 2006; 21: 365-372. (Pubitemid 44594423)
13. World Health Organization. Making choices in health WHO guide to cost-effectiveness analysis. Geneva, Switzerland: WHO, 2003.
14. Wu G, Gong Y, Li Y, et al. A study of the effect of TB control programs on disease burden. Chinese J Hospital Administration 2001; 17: 4.
15. Sassi F. Calculating QALYs, comparing QALY and DALY calculations. Health Policy Plann 2006; 21: 402-408. (Pubitemid 44594426)
16. Liao C M, Cheng Y H, Lin Y J, et al. A probabilistic transmission and population dynamic model to assess tuberculosis infection risk. Risk analysis: an official publication of the Society for Risk Analysis 2012; 32: 1420-1432.
17. Vynnycky E, Fine P E. The natural history of tuberculosis: the implications of age-dependent risks of disease and the role of reinfection. Epidemiol Infect 1997; 119: 183-201. (Pubitemid 27474799)
18. World Health Organization. Tuberculosis Fact Sheet. Geneva, Switzerland: WHO, 2012. http://www.who.int/mediacentre/factsheets/en/. Accessed May 2014.
19. Wang S, Wang X, Zhao X, et al. Research on treatment efficacy of the patients with drug resistance in the project for drug resistance surveillance in Guangdong and Zhejiang provinces. The Journal of the Chinese Antituberculosis Association 2005; 27: 4.
20. World Health Organization. Investing in health research and development: report of the ad hoc committee on health research relating to future intervention options. Geneva, Switzerland: WHO, 1996.
21. Glaziou P, Floyd K, Korenromp E L, et al. Lives saved by tuberculosis control and prospects for achieving the 2015 global target for reducing tuberculosis mortality. Bull World Health Organ 2011; 89: 573-582.
22. Currie C S, Floyd K, Williams B G, et al. Cost, affordability and cost-effectiveness of strategies to control tuberculosis in countries with high HIV prevalence. BMC Public Health 2005; 5: 130.
23. Baltussen R, Floyd K, Dye C. Cost-effectiveness analysis of strategies for tuberculosis control in developing countries. BMJ 2005; 331: 1364.
24. Murray C J, DeJonghe E, Chum H J, et al. Cost effectiveness of chemotherapy for pulmonary tuberculosis in three sub-Saharan African countries. Lancet 1991; 338: 1305-1308.
25. Wilton P, Smith R D, Coast J, et al. Directly observed treatment for multidrug-resistant tuberculosis: an economic evaluation in the United States of America and South Africa. Int J Tuberc Lung Dis 2001; 5: 1137-1142. (Pubitemid 34033215)
26. China economy yearbook. Chinese Academy of Social Sciences yearbooks. Vol 1: Economy. Leiden, The Netherlands: Brill Press, 2008.
27. World Health Organization. Cost-effectiveness thresholds. Geneva, Switzerland: WHO, 2014. http://www.who.int/choice/costs/CER-thresholds/en/. Accessed May 2014.
28. Steffen R, Menzies D, Oxlade O, et al. Patients' costs and cost-effectiveness of tuberculosis treatment in DOTS and non-DOTS facilities in Rio de Janeiro, Brazil. PLOS ONE 2010; 5: e14014.
29. Akachi Y, Zumla A, Atun R. Investing in improved performance of national tuberculosis programs reduces the tuberculosis burden: analysis of 22 high-burden countries, 2002-2009. J Infect Dis 2012; 205 (Suppl 2): S284-S292.
30. Singla R, Sarin R, Khalid U K, et al. Seven-year DOTS-Plus pilot experience in India: results, constraints and issues. Int J Tuberc Lung Dis 2009; 13: 976-981.